Healthcare / Drug Manufacturers - GeneralShenzhen
$20.73
+0.03 (+0.14%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $25.2M · quality 63.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
47/100
C
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.2B
P/E
23.6x
↑EV/EBITDA
12.5x
↑ROE
9.1%
↑Gross Margin
45.6%
↓Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+8.0%
FCF CAGR
-22.8%
FCF margin
4.7%
FCF / Net income
0.19x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $532.3M · net income $135.9M · FCF $25.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $532.3M | $532.3M | $471.5M | $397.5M | $422.8M |
| Net Income | $135.9M | $135.9M | $122.6M | $104.7M | $107.6M |
| EBITDA | $180.7M | $180.7M | $158.9M | $134.1M | $138.2M |
| EPS | 0.89 | 0.89 | 0.82 | 0.76 | 0.96 |
| Gross Margin | 45.6% | 45.6% | 41.5% | 41.1% | 37.4% |
| Operating Margin | 27.9% | 27.9% | 26.4% | 27.4% | 27.4% |
| Net Margin | 25.5% | 25.5% | 26.0% | 26.3% | 25.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 |
| Current Ratio | 14.65 | 14.65 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $25.2M | $25.2M | $102.4M | $23.2M | $54.8M |
| Returns | |||||
| ROE | 9.1% | 9.1% | 9.1% | 8.4% | 22.9% |
| Valuation | |||||
| P/E | 23.56 | 23.56 | 22.12 | 26.40 | — |
| EV/EBITDA | 12.53 | 12.53 | 10.60 | 13.57 | — |
| P/B | 2.12 | 2.12 | 2.02 | 2.21 | — |
| Growth & Yield | |||||
| Revenue Growth | 12.9% | 12.9% | 18.6% | -6.0% | — |
| EPS Growth | 8.5% | 8.5% | 7.4% | -20.7% | — |
| Dividend Yield | 0.6% | 0.6% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
27.4%
EPS terminal req.
$1.84
Spread vs growth
-18.8%
5Y implied EPS CAGR
20.1%
EPS terminal req.
$2.23
Spread vs growth
-11.6%
10Y implied EPS CAGR
14.9%
EPS terminal req.
$3.58
Spread vs growth
-6.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+2.8%
Start / end P/E
24.7x → 23.3x
EPS bridge
0.82 → 0.89
Residual
-0.5%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.